physIQ Announces Collaboration with InCarda Therapeutics and Syneos Health

Article

physIQ has announced a strategic collaboration with InCarda Therapeutics, Inc. Syneos Health recommended physIQ’s monitoring solution to help advance InCarda’s clinical study of InRhythm™ (orally inhaled flecainide) in patients with atrial fibrillation.

Read more about the new partnership here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Recent Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.